Quantum Biopharma Ltd. amended its foreign private issuer report through Amendment No. 1, with registration reference 333-276264. The initial report remains effective except where the amendment changes it, and the amendment is treated as part of the initial report for investors reviewing the company’s disclosed record.

Key Highlights

  • Quantum Biopharma filed Amendment No. 1 to its Foreign Private Issuer Report on Form 6-K.
  • Quantum Biopharma identified Form 20-F as the annual-report framework it uses.
  • The amendment is treated as part of the initial report from the date it was furnished, except where later reports supersede it.

Quantum Biopharma Ltd. (NASDAQ: QNTM) amended its foreign private issuer report through Amendment No. 1, while stating that the initial report remains unchanged except for the matters covered by the amendment. The record carries reference 333-276264.

Amendment No. 1 Updates Existing Report

Quantum Biopharma identifies itself as a foreign private issuer and marks Form 20-F as the annual-report framework it files. Form 40-F is not selected. The report names Quantum Biopharma Ltd. and states that the amendment is deemed part of the Initial Report.

Initial Report Remains in Effect

The amended material is treated as part of the initial report from the date that report was furnished. Quantum Biopharma also states that later reports can supersede the incorporated material. The document is signed on behalf of Quantum Biopharma Ltd. by an authorised representative under the Securities Exchange Act of 1934.